1. Hepatocellular carcinoma in patients with no identifiable risk factors. (March 2019) Authors: McIntyre, C.A.; Chou, J.F.; Gonen, M.; Shia, J.; Balachandran, V.P.; Kingham, T.P.; Allen, P.J.; Drebin, J.A.; Jarnagin, W.R.; D'Angelica, M.I. Journal: HPB Issue: Volume 21(2019)Supplement 1 Page Start: S88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Longitudinal follow-up of a prospective phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma reveals distinct patterns of survivorship. (March 2019) Authors: Datta, J.; McIntyre, C.A.; Chou, J.; Askan, G.; Drebin, J.A.; Capanu, M.; Balachandran, V.P.; D'Angelica, M.I.; Iacobuzio-Donahue, C.; Basturk, O.; Jarnagin, W.R.; Kingham, T.P.; Allen, P.J.; O'Reilly, E.M. Journal: HPB Issue: Volume 21(2019)Supplement 1 Page Start: S58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗